Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase

Endocrine therapy resistance is a primary cause of clinical breast cancer treatment failure. The p38 mitogen activated protein kinase (MAPK) signaling pathway is known to promote ligand independent tumor growth and resistance to endocrine therapy. In this study, we investigated the therapeutic poten...

Full description

Saved in:
Bibliographic Details
Main Authors: Antoon, James W, Bratton, Melyssa R, Guillot, Lori M, Wadsworth, Scott, Salvo, Virgilio A, Elliott, Steven, McLachlan, John A, Burow, Matthew E
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2012
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3410584/
https://ncbi.nlm.nih.gov/pubmed/22860234
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items